Piper Jaffray Upgrades Allscripts To Overweight

According to Piper Jaffray, Allscripts MDRX is upgraded to Overweight. Piper Jaffray said that it is maintaining its $22 price target after the company reported Q2 earnings ahead of expectations. “We believe much of the integration risk from the Eclipsys merger is behind the company, or at the very least priced in. Allscripts has the leading market share among physicians, which is a significant competitve advantage when competing for wallet-share.” Allscripts closed yesterday at $16.74.